T-DM1 shows across-board benefits as EMILIA breast cancer data unveiled
This article was originally published in Scrip
Women treated with Genentech's antibody-drug conjugate T-DM1 (trastuzumab emtansine) lived nearly six months longer than HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine in the Phase III EMILIA study used to support applications for regulatory approval of the closely watched second-line therapy.
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.